Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.78 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.78 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.49 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 4/20 | 0.47 |
| ▸ | CA2 | P00918 | 4/20 | 0.47 |
| ▸ | CA12 | O43570 | 3/20 | 0.47 |
| ▸ | CA9 | Q16790 | 3/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
| ▸ | HTR3A | P46098 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10003354 | 0.89 | CYP4F2 (0.60) | CYP4F2CYP4A11BAZ2BBAZ2ACA1 | |
| SCHEMBL9827680 | 0.88 | CYP4F2 (0.62) | CYP4F2CYP4A11BAZ2BBAZ2ACA1 | |
| SCHEMBL27318143 | 0.88 | CYP4F2 (0.61) | CYP4F2CYP4A11BAZ2BBAZ2ACA1 | |
| SCHEMBL22098189 | 0.88 | CYP4F2 (1.00) | CYP4F2CYP4A11BAZ2BBAZ2ACA1 | |
| SCHEMBL522636 | 0.86 | CYP4F2 (0.57) | CYP4F2CYP4A11BAZ2BBAZ2ACA1 | |
| SCHEMBL20077738 | 0.84 | SMN1; SMN2 (0.57) | CYP4F2CYP4A11BAZ2BBAZ2ACA1 | |
| SCHEMBL1830479 | 0.84 | CYP4F2 (0.55) | CYP4F2CYP4A11CA1CA2CA12 | |
| SCHEMBL7410301 | 0.84 | CYP4F2 (0.68) | CYP4F2CYP4A11CA1CA2CA12 | |
| SCHEMBL6289032 | 0.83 | CYP4F2 (0.66) | CYP4F2CYP4A11CA1CA2CA12 | |
| SCHEMBL1702411 | 0.83 | CYP4F2 (0.66) | CYP4F2CYP4A11CA1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0955294-B1 | Imidazolyl-alkenoic acid | SMITHKLINE BEECHAM CORP (US) | 2003-09-24 | — | — | EP | disclosed |
| US-20030171422-A1 | New nitromethyl ketones, process for preparing them and compositions containing them | MERCK PATENT GMBH (DE) | 2003-09-11 | — | — | US | disclosed |
| US-6559185-B2 | Nitromethyl ketone compounds having aldose reduction inhibiting properties and methods for their use | MERCK PATENT GMBH (DE) | 2003-05-06 | — | — | US | disclosed |
| US-20030069312-A1 | Antidiabetic agents | LARDY CLAUDE (FR) | 2003-04-10 | — | — | US | disclosed |
| US-6043281-A | ALDOSE REDUCTASE INHIBITORS; TREATMENT OR PREVENTION OF COMPLICATIONS OF DIABETES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2000-03-28 | — | — | US | disclosed |
| EP-0983226-A1 | NEW NITROMETHYL KETONES, PROCESS FOR PREPARING THEM AND COMPOSITIONS CONTAINING THEM | MERCK PATENT GmbH (DE) | 2000-03-08 | — | — | EP | disclosed |
| CN-1048159-C | Imidazolyl-alkenoic acids | SMITHKLINE BEECHAM CORP (US) | 2000-01-12 | — | — | CN | disclosed |
| EP-0955294-A2 | Imidazolyl-alkenoic acid | SMITHKLINE BEECHAM CORPORATION (US) | 1999-11-10 | — | — | EP | disclosed |
| US-5932765-A | REDUCTASE INHIBITORS | MERCK PATENT GESELLSCHAFT MIT (DE) | 1999-08-03 | — | — | US | disclosed |
| WO-1998052906-A1 | NEW NITROMETHYL KETONES, PROCESS FOR PREPARING THEM AND COMPOSITIONS CONTAINING THEM | MERCK PATENT GMBH (DE) | 1998-11-26 | — | — | WO | disclosed |
| US-5418250-A | Hypotensive | SMITHKLINE BEECHAM CORPORATION (US) | 1995-05-23 | — | — | US | disclosed |
| US-5312828-A | Substituted imidazoles having angiotensin II receptor blocking activity | SMITHKLINE BEECHAM CORPORATION A CORP. OF PENNSYLVANIA | 1994-05-17 | — | — | US | disclosed |
| CN-1079649-A | Preparation contains the method for the pharmaceutical composition of imidazolyl-alkenoic acids | SMITHKLINE BEECHAM CORP (US) | 1993-12-22 | — | — | CN | disclosed |
| CN-1079648-A | Preparation contains the method for the pharmaceutical composition of imidazolyl-alkenoic acids | SMITHKLINE BEECHAM CORP (US) | 1993-12-22 | — | — | CN | disclosed |
| US-5185351-A | Hypotensive agents; for treatment of congestive heart failure, renal failure and glaucoma | SMITHKLINE BEECHAM CORPORATION (US) | 1993-02-09 | — | — | US | disclosed |
| EP-0150892-B1 | SUBSTITUTED ALKYLIDENE IMIDAZOLES | G.D. Searle & Co. (US) | 1991-04-24 | — | — | EP | disclosed |
| EP-0403158-A2 | Imidazolyl-alkenoic acids | SMITHKLINE BEECHAM CORPORATION (US) | 1990-12-19 | — | — | EP | disclosed |
| EP-0403159-A2 | Imidazolyl-alkenoic acids | SMITHKLINE BEECHAM CORPORATION (US) | 1990-12-19 | — | — | EP | disclosed |
| US-4837333-A | SELECTIVE INHIBITOR OF THROMBOXANE SYNTHETASE ENZYME | G. D. SEARLE & CO. (US) | 1989-06-06 | — | — | US | disclosed |
| EP-0150892-A2 | Substituted alkylidene imidazoles | G.D. Searle & Co. (US) | 1985-08-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069312-A1 | Antidiabetic agents | SLC5A1, SLC5A2, GPR119 | CYP4F2 232/4885CYP4A11 138/4885BAZ2B 3391/4885 |
| US-20030171422-A1 | New nitromethyl ketones, process for preparing them and compositions containing them | AKR1B1, AKR1A1, AKR1C1 | CYP4F2 240/4885CYP4A11 35/4885BAZ2B 1970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.